N-benzyl-4-(4-chlorophenyl)-4-fluoropiperidine: | 324002-50-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-benzyl-4-(4-chlorophenyl)-4-fluoropiperidine:
• 英文别名: 4-(4-Chlorophenyl)-4-fluoro-1-(phenylmethyl)piperidine；1-benzyl-4-(4-chlorophenyl)-4-fluoropiperidine
• CAS: 324002-50-8
• 化学式: C₁₈H₁₉ClFN
• 分子量: 303.807
• InChiKey: NJKHUYNYUNZYBO-UHFFFAOYSA-N

物化性质

• 沸点：
  381.3±42.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-benzyl-4-(4-chlorophenyl)-4-fluoropiperidine: 在 1-氯乙基氯甲酸酯 作用下， 以 二氯甲烷 、 甲醇 为溶剂， 反应 2.0h， 以100%的产率得到4-fluoro-4-(4-chlorophenyl)-1-piperidine hydrochloride
  参考文献：
  名称：

  Synthesis of 4-substituted 4-arylpiperidines

  摘要：

  Several novel 4-substituted 4-arylpiperidines were synthesized. The chemistry leading to 4-(4-chlorophenyl)-4-fluoropiperidine (6), 4-azido-4-(4-chlorophenyl)piperidine (7) and 4-(4-chlorophenyl)-4methylpiperidine (8) is described. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(00)01610-5
• 作为产物：
  描述：

  4-(4-氯苯基)-4-羟基哌啶 在 二乙胺基三氟化硫 、 potassium carbonate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-benzyl-4-(4-chlorophenyl)-4-fluoropiperidine:
  参考文献：
  名称：

  Synthesis of 4-substituted 4-arylpiperidines

  摘要：

  Several novel 4-substituted 4-arylpiperidines were synthesized. The chemistry leading to 4-(4-chlorophenyl)-4-fluoropiperidine (6), 4-azido-4-(4-chlorophenyl)piperidine (7) and 4-(4-chlorophenyl)-4methylpiperidine (8) is described. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(00)01610-5

文献信息

• CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20160031908A1

  公开（公告）日：2016-02-04

  Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.

  揭示了新颖的化合物以及治疗与异常白细胞召集和/或激活相关的疾病的方法。该方法包括向需要的受试者施用代表的化合物的有效量： 或其生理上可接受的盐。
• Chemokine receptor anagonists and methods of use therefor
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20020169155A1

  公开（公告）日：2002-11-14

  Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: 1 or physiologically acceptable salt thereof.

  揭示了新颖的化合物以及一种治疗与异常白细胞召集和/或激活相关疾病的方法。该方法包括向需要的受试者施用化合物1或其生理上可接受的盐的有效量。
• CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR
  申请人：——

  公开号：US20020119973A1

  公开（公告）日：2002-08-29

  Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: 1 and physiologically acceptable salts thereof. 2

  披露了新颖的化合物以及一种治疗与异常白细胞招募和/或激活相关疾病的方法。该方法包括向需要治疗的主体施用一种有效量的化合物，该化合物由以下结构表示： 1 以及它们的生理可接受的盐。 2
• Chemokine receptor antagonists and methods of use thereof
  申请人：Luly R. Jay

  公开号：US20050070549A1

  公开（公告）日：2005-03-31

  Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: formula (1) or physiologically acceptable salt thereof.

  揭示了新化合物和一种治疗与异常白细胞召集和/或激活相关疾病的方法。该方法包括向需要的受试者施用由以下公式（1）表示的化合物或其生理上可接受的盐的有效量。
• Chemokine receptor antagonists and methods of use therefor
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20030045516A1

  公开（公告）日：2003-03-06

  Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: 1 and physiologically acceptable salts thereof.

  本发明涉及新型化合物和治疗与异常白细胞招募和/或激活相关的疾病的方法。该方法包括向需要治疗的受体内注射有效量的化合物1及其生理上可接受的盐。